KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to $501.1 million.

  • Alnylam Pharmaceuticals' Cash from Investing Activities rose 175655.21% to $501.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $420.6 million, marking a year-over-year increase of 23808.42%. This contributed to the annual value of -$116.8 million for FY2024, which is 6526.24% up from last year.
  • Alnylam Pharmaceuticals' Cash from Investing Activities amounted to $501.1 million in Q3 2025, which was up 175655.21% from -$141.4 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' Cash from Investing Activities' 5-year high stood at $501.1 million during Q3 2025, with a 5-year trough of -$413.4 million in Q4 2021.
  • Its 5-year average for Cash from Investing Activities is -$4.4 million, with a median of -$30.2 million in 2024.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Cash from Investing Activities plummeted by 77500.99% in 2021, and later surged by 175655.21% in 2025.
  • Alnylam Pharmaceuticals' Cash from Investing Activities (Quarter) stood at -$413.4 million in 2021, then soared by 66.16% to -$139.9 million in 2022, then plummeted by 72.01% to -$240.7 million in 2023, then skyrocketed by 78.01% to -$52.9 million in 2024, then skyrocketed by 1047.09% to $501.1 million in 2025.
  • Its Cash from Investing Activities was $501.1 million in Q3 2025, compared to -$141.4 million in Q2 2025 and $113.8 million in Q1 2025.